Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Seres Therapeutics, Inc. (MCRB)
USD5.31
-0.03 (-0.47%)
US NASDAQ Healthcare Biotechnology
Address
200 Sidney Street 2139
Cambridge, MA, US
Cambridge, MA, US
CEO
Richard N. Kender
Website
serestherapeutics.com
IPO
2015-06-26
CIK 1609809 ISIN US81750R2013
Description
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
News Sentiment (7d)
4 articles
- Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript Seeking Alpha
- Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study MarketBeat
- Seres Therapeutics Posts Early Data for Cancer Therapy Complication Benzinga
- Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment GlobeNewsWire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.31
-0.03 (-0.47%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
66.7K
Beta
0.11
Float Shares
7.28M
Free Float %
75.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.53% | -0.13% | -4.33% | -3.16% | -50.28% | -46.51% | +1.02% | -92.24% | -98.10% | -98.30% | -99.23% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (18 ratings, all time)
Buy
Price Targets & DCF
Current price
5.31
Low
1.25
-76.5%
Consensus
1.25
-76.5%
Median
1.25
-76.5%
High
1.25
-76.5%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | -2 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
1.25
-76.5%
|
Quality scores
Altman Z-Score
-12.63
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+103.4% ★ Q1'26: -155.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-14,939.2% Q1'26: -4,569.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-11,910.1% Q1'26: -5,839.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-115.4% Q1'26: -108.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+14.2% Q1'26: +10.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.92× Q1'26: -1.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
21.77M
est: 21.57M (+0.9%)
|
32.10M
est: 31.65M (+1.4%)
|
28.27M
est: 28.63M (-1.3%)
|
34.51M
est: 33.12M (+4.2%)
|
33.22M
est: 22.59M (+47.0%)
|
144.93M
est: 149.82M (-3.3%)
|
—
est: 13.76M (-100.0%)
|
—
est: 126.85M (-100.0%)
|
—
est: 31.00M (-100.0%)
|
789.0K
est: 266.7K (+195.9%)
|
716.0K
716.0K – 716.0K
+168.5% YoY
|
716.0K
716.0K – 716.0K
+0.0% YoY
|
716.0K
716.0K – 716.0K
+0.0% YoY
|
249.6K
249.6K – 249.6K
-65.1% YoY
|
| EBITDA |
-88.63M
est: 6.94M (-1,377.5%)
|
-82.12M
est: 10.18M (-906.5%)
|
-91.08M
est: 9.21M (-1,089.0%)
|
-62.17M
est: 10.65M (-683.5%)
|
-77.31M
est: 7.27M (-1,163.6%)
|
-56.72M
est: 48.20M (-217.7%)
|
-170.93M
est: 4.43M (-3,962.3%)
|
-181.42M
est: 40.81M (-544.5%)
|
-120.30M
est: 9.97M (-1,306.2%)
|
-89.84M
est: 85.8K (-104,814.8%)
|
230.4K
230.4K – 230.4K
+168.5% YoY
|
230.4K
230.4K – 230.4K
+0.0% YoY
|
230.4K
230.4K – 230.4K
+0.0% YoY
|
80.3K
80.3K – 80.3K
-65.1% YoY
|
| EBIT |
-92.84M
est: 6.76M (-1,473.1%)
|
-89.38M
est: 9.92M (-1,000.8%)
|
-98.94M
est: 8.97M (-1,202.5%)
|
-69.78M
est: 10.38M (-772.0%)
|
-86.20M
est: 7.08M (-1,316.9%)
|
-62.67M
est: 46.97M (-233.4%)
|
-177.56M
est: 4.31M (-4,217.2%)
|
-187.66M
est: 39.77M (-571.9%)
|
-125.77M
est: 9.72M (-1,394.1%)
|
-93.97M
est: 83.6K (-112,500.1%)
|
224.5K
224.5K – 224.5K
+168.5% YoY
|
224.5K
224.5K – 224.5K
+0.0% YoY
|
224.5K
224.5K – 224.5K
+0.0% YoY
|
78.3K
78.3K – 78.3K
-65.1% YoY
|
| Net Income |
-91.58M
est: -372.44M (+75.4%)
|
-89.38M
est: -349.21M (+74.4%)
|
-98.94M
est: -374.26M (+73.6%)
|
-70.28M
est: -198.39M (+64.6%)
|
-89.13M
est: -171.33M (+48.0%)
|
-65.58M
est: -95.66M (+31.4%)
|
-250.16M
est: -336.25M (+25.6%)
|
-113.72M
est: -5.51M (-1,963.4%)
|
136.0K
est: -28.84M (+100.5%)
|
5.70M
est: 2.34M (+143.9%)
|
-81.51M
-81.51M – -81.51M
-3,589.9% YoY
|
-91.18M
-91.18M – -91.18M
-11.9% YoY
|
-101.20M
-101.20M – -101.20M
-11.0% YoY
|
-78.05M
-78.05M – -78.05M
+22.9% YoY
|
| SGA |
32.62M
est: 19.00M (+71.7%)
|
34.04M
est: 27.88M (+22.1%)
|
32.60M
est: 25.22M (+29.3%)
|
24.75M
est: 29.17M (-15.2%)
|
30.78M
est: 19.90M (+54.6%)
|
69.26M
est: 131.98M (-47.5%)
|
70.26M
est: 12.12M (+479.9%)
|
77.50M
est: 1.35B (-94.2%)
|
53.18M
est: 329.25M (-83.8%)
|
39.16M
est: 2.83M (+1,282.5%)
|
7.60M
7.60M – 7.60M
+168.5% YoY
|
7.60M
7.60M – 7.60M
+0.0% YoY
|
7.60M
7.60M – 7.60M
+0.0% YoY
|
2.65M
2.65M – 2.65M
-65.1% YoY
|
| EPS |
-46.00
est: -47.93 (+4.0%)
|
-44.19
est: -44.94 (+1.7%)
|
-48.57
est: -48.17 (-0.8%)
|
-24.81
est: -25.53 (+2.8%)
|
-22.34
est: -22.05 (-1.3%)
|
-14.30
est: -12.31 (-16.2%)
|
-46.29
est: -43.28 (-7.0%)
|
-17.77
est: -0.62 (-2,759.8%)
|
-18.86
est: -2.40 (-686.1%)
|
0.64
est: 0.26 (+143.0%)
|
-9.19
-9.19 – -9.19
-3,589.9% YoY
|
-10.28
-10.28 – -10.28
-11.9% YoY
|
-11.41
-11.41 – -11.41
-11.0% YoY
|
-8.80
-8.80 – -8.80
+22.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-01 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-41.96M
OE per share TTM
-4.62
Owner's Yield
-55.01%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
236.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
40
Total invested
36.37M
Insider transactions (90d)
0
Beneficial owners (>5%)
24
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Federated Hermes, Inc. | 17.98M | 14.50% | 17.98M | — | 17.98M | — | HC | Citizenship or place of Organization | 2022-07-11 | ↗ |
| 2 | J. Christopher Donahue | 17.98M | 14.50% | — | 17.98M | — | 17.98M | IN | Citizenship or place of Organization | 2022-07-11 | ↗ |
| 3 | Rhodora J. Donahue | 17.98M | 14.50% | — | 17.98M | — | 17.98M | IN | Citizenship or place of Organization | 2022-07-11 | ↗ |
| 4 | Thomas R. Donahue | 17.98M | 14.50% | — | 17.98M | — | 17.98M | IN | Citizenship or place of Organization | 2022-07-11 | ↗ |
| 5 | Voting Shares Irrevocable Trust | 17.98M | 14.50% | 17.98M | — | 17.98M | — | OO | Citizenship or place of Organization | 2022-07-11 | ↗ |
| 6 | Nestlé S.A. | 7.59M | 6.10% | — | 7.59M | — | 7.59M | CO | — | 2022-07-22 | ↗ |
| 7 | Société des Produits Nestlé S.A. | 7.50M | 6.00% | — | 7.50M | — | 7.50M | CO | — | 2022-07-22 | ↗ |
| 8 | (1)Names of reporting persons. BlackRock, Inc. | 7.34M | 5.70% | 7.26M | — | 7.34M | — | HC | Delaware | 2024-01-29 | ↗ |
| 9 | Nikko Asset Management Americas, Inc. | 7.10M | 10.15% | — | 4.25M | — | 7.10M | IA | USA | 2019-09-06 | ↗ |
| 10 | 10. | 6.89M | 17.70% | — | 6.89M | — | 6.89M | CO | Delaware | 2015-07-06 | ↗ |
| 11 | (1) BlackRock, Inc. | 6.46M | 5.20% | 6.23M | — | 6.46M | — | HC | Delaware | 2023-02-03 | ↗ |
| 12 | Nikko Asset Management Co., Ltd. (“NAM”) | 5.82M | 6.38% | — | 5.82M | — | 5.82M | FI, IA, HC | Japan | 2021-02-05 | ↗ |
| 13 | Sumitomo Mitsui Trust Holdings, Inc. (“SMTH”) | 5.82M | 6.38% | — | 5.82M | — | 5.82M | FI, HC | Japan | 2021-02-05 | ↗ |
| 14 | EIN #00-0000000 | 5.06M | 5.50% | — | 5.06M | — | 5.06M | IA, HC | Jersey, Channel Islands | 2022-02-11 | ↗ |
| 15 | The Vanguard Group - 23-1945930 | 4.68M | 5.09% | — | 128.9K | 4.50M | 178.2K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 16 | T. ROWE PRICE ASSOCIATES, INC. | 1.31M | 5.60% | — | 9.89M | — | 10.00M | IA | BOSTON, MASSACHUSETTS | 2021-10-12 | ↗ |
| 17 | of 17 | 10.00 | 12.00% | — | 599.3K | — | 599.3K | OO | Delaware United States America | 2016-02-16 | ↗ |
| 18 | NIMCO US, Inc. | — | 0.00% | — | — | — | — | CO | — | 2022-07-22 | ↗ |
| 19 | Nestle Health Science US Holdings, Inc. | — | 0.00% | — | — | — | — | CO | — | 2022-07-22 | ↗ |
| 20 | Nestlé US Holdco, Inc. | — | 0.00% | — | — | — | — | CO | — | 2022-07-22 | ↗ |
| 21 | Peter Kolchinsky | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2022-02-14 | ↗ |
| 22 | RA Capital Healthcare Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 23 | RA Capital Management, L.P. | — | 0.00% | — | — | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 24 | Rajeev Shah | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
40
-4 vs prev Q
New positions
8
Closed positions
10
Increased
22
Reduced
8
Put/Call ratio
0.73
Calls held
173.6K
Puts held
127.0K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FLAGSHIP PIONEERING INC. | 1.16M +— (+0.0%) | 17.24M -5.0M (-22.5%) | 13.20% -0.023 pp | 5.32% -2.281 pp | USD11.11 +33.9% | 3 qtrs — |
| 2 | VANGUARD GROUP INC | 324.2K +12.3K (+4.0%) | 4.82M -1.2M (-19.6%) | 3.70% +0.135 pp | 0.00% +0.000 pp | USD11.75 +26.6% | 3 qtrs — |
| 3 | MARSHALL WACE, LLP | 120.2K -5.4K (-4.3%) | 1.79M -628.3K (-26.0%) | 1.37% -0.064 pp | 0.00% -0.001 pp | USD13.32 +11.7% | 3 qtrs — |
| 4 | BLACKROCK, INC. | 103.6K +1.6K (+1.5%) | 1.54M -421.8K (-21.5%) | 1.18% +0.016 pp | 0.00% +0.000 pp | USD11.22 +32.6% | 3 qtrs — |
| 5 | VONTOBEL HOLDING LTD. | 103.2K +4.7K (+4.8%) | 1.54M -359.2K (-19.0%) | 1.18% +0.052 pp | 0.00% -0.001 pp | USD12.71 +17.1% | 3 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 86.1K +1.2K (+1.4%) | 1.28M -353.4K (-21.6%) | 0.98% +0.012 pp | 0.00% +0.000 pp | USD11.16 +33.3% | 3 qtrs — |
| 7 | CAPTION MANAGEMENT, LLC | 75.0K +— (+0.0%) | 1.12M -327.0K (-22.7%) | 0.86% -0.002 pp | 0.01% -0.004 pp | USD19.24 -22.7% | 2 qtrs — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 68.7K -247.6K (-78.3%) | 1.02M -5.1M (-83.2%) | 0.78% -2.833 pp | 0.00% -0.001 pp | USD17.10 -13.0% | 3 qtrs — |
| 9 | 683 CAPITAL MANAGEMENT, LLC | 52.3K +52.3K (+100.0%) | 778.4K +778.4K (+100.0%) | 0.60% +0.597 pp | 0.03% +0.034 pp | USD14.88 +0.0% | 1 qtrs NEW |
| 10 | STATE STREET CORP | 33.9K +4.2K (+14.0%) | 504.4K -67.6K (-11.8%) | 0.39% +0.047 pp | 0.00% +0.000 pp | USD12.27 +21.3% | 3 qtrs — |
| 11 | LION POINT CAPITAL, LP | 31.6K +4.4K (+16.3%) | 469.8K -52.4K (-10.0%) | 0.36% +0.050 pp | 2.43% -0.535 pp | USD14.24 +4.5% | 3 qtrs — |
| 12 | CITADEL ADVISORS LLC | 31.4K +533.0 (+1.7%) | 467.5K -126.7K (-21.3%) | 0.36% +0.006 pp | 0.00% +0.000 pp | USD19.17 -22.4% | 2 qtrs — |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 31.4K -34.0 (-0.1%) | 466.8K -137.4K (-22.7%) | 0.36% -0.001 pp | 0.00% +0.000 pp | USD11.11 +33.9% | 3 qtrs — |
| 14 | JANE STREET GROUP, LLC | 29.9K -38.2K (-56.1%) | 445.0K -865.3K (-66.0%) | 0.34% -0.437 pp | 0.00% 0.000 pp | USD19.24 -22.7% | 2 qtrs — |
| 15 | SCHONFELD STRATEGIC ADVISORS LLC | 29.1K +155.0 (+0.5%) | 433.0K -123.9K (-22.2%) | 0.33% +0.001 pp | 0.00% -0.001 pp | USD19.22 -22.6% | 2 qtrs — |
| 16 | TWO SIGMA INVESTMENTS, LP | 25.7K +25.7K (+100.0%) | 383.1K +383.1K (+100.0%) | 0.29% +0.294 pp | 0.00% +0.001 pp | USD14.88 +0.0% | 1 qtrs NEW |
| 17 | MORGAN STANLEY | 25.1K +6.8K (+37.0%) | 373.9K +21.1K (+6.0%) | 0.29% +0.077 pp | 0.00% +0.000 pp | USD15.53 -4.2% | 3 qtrs — |
| 18 | AMERICAN CENTURY COMPANIES INC | 16.3K +16.3K (+100.0%) | 242.1K +242.1K (+100.0%) | 0.19% +0.186 pp | 0.00% +0.000 pp | USD14.88 +0.0% | 1 qtrs NEW |
| 19 | NORTHERN TRUST CORP | 14.8K +2.7K (+22.0%) | 219.7K -13.1K (-5.6%) | 0.17% +0.030 pp | 0.00% +0.000 pp | USD11.79 +26.2% | 3 qtrs — |
| 20 | OMERS ADMINISTRATION CORP | 14.4K +14.4K (+100.0%) | 214.3K +214.3K (+100.0%) | 0.16% +0.164 pp | 0.00% +0.002 pp | USD14.88 +0.0% | 1 qtrs NEW |
| 21 | INVESCO LTD. | 14.4K +3.9K (+37.5%) | 213.7K +12.8K (+6.4%) | 0.16% +0.045 pp | 0.00% +0.000 pp | USD18.05 -17.6% | 2 qtrs — |
| 22 | GOLDMAN SACHS GROUP INC | 14.3K +14.3K (+100.0%) | 213.4K +213.4K (+100.0%) | 0.16% +0.164 pp | 0.00% +0.000 pp | USD14.88 +0.0% | 1 qtrs NEW |
| 23 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 12.7K +12.7K (+100.0%) | 189.5K +189.5K (+100.0%) | 0.15% +0.145 pp | 0.00% +0.002 pp | USD14.88 +0.0% | 1 qtrs NEW |
| 24 | BARCLAYS PLC | 7.4K +6.0K (+427.8%) | 110.6K +83.5K (+308.2%) | 0.08% +0.069 pp | 0.00% +0.000 pp | USD15.71 -5.3% | 2 qtrs — |
| 25 | UBS GROUP AG | 4.2K -8.5K (-66.7%) | 62.9K -181.1K (-74.2%) | 0.05% -0.097 pp | 0.00% +0.000 pp | USD14.41 +3.3% | 3 qtrs — |
| 26 | SBI SECURITIES CO., LTD. | 3.5K +— (+0.0%) | 51.8K -15.2K (-22.7%) | 0.04% 0.000 pp | 0.00% 0.000 pp | USD0.70 +2,025.7% | 4 qtrs — |
| 27 | FMR LLC | 1.7K -142.0 (-7.5%) | 25.9K -10.3K (-28.5%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD11.11 +33.9% | 3 qtrs — |
| 28 | — | 1.5K +1.5K (+100.0%) | 22.0K +22.0K (+100.0%) | 0.02% +0.017 pp | 0.01% +0.012 pp | USD14.88 +0.0% | 1 qtrs NEW |
| 29 | SIMPLEX TRADING, LLC | 1.2K -1.6K (-56.1%) | 18.3K -35.7K (-66.1%) | 0.01% -0.018 pp | 0.00% +0.000 pp | USD19.24 -22.7% | 2 qtrs — |
| 30 | BNP PARIBAS ARBITRAGE, SNC | 773.00 +561.0 (+264.6%) | 11.5K +7.4K (+182.0%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD13.84 +7.5% | 3 qtrs — |
| 31 | WELLS FARGO & COMPANY/MN | 260.00 +250.0 (+2,500.0%) | 3.9K +3.7K (+1,915.1%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD14.73 +1.0% | 3 qtrs — |
| 32 | BANK OF AMERICA CORP /DE/ | 195.00 -5.1K (-96.4%) | 2.9K -99.9K (-97.2%) | 0.00% -0.059 pp | 0.00% +0.000 pp | USD18.95 -21.5% | 3 qtrs — |
| 33 | PHYSICIAN WEALTH ADVISORS, INC. | 142.00 +— (+0.0%) | 2.1K -620.0 (-22.7%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD11.11 +33.9% | 3 qtrs — |
| 34 | SOUND INCOME STRATEGIES, LLC | 8.00 +— (+0.0%) | 128.00 -28.0 (-17.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD19.13 -22.2% | 2 qtrs — |
| 35 | ADVISOR GROUP HOLDINGS, INC. | 8.00 +— (+0.0%) | 119.00 -32.0 (-21.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.00 +35.3% | 3 qtrs — |
| 36 | ALLWORTH FINANCIAL LP | 4.00 +4.0 (+100.0%) | 60.00 +60.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD14.75 +0.9% | 1 qtrs NEW |
| 37 | SRS CAPITAL ADVISORS, INC. | 2.00 +— (+0.0%) | 30.00 -8.0 (-21.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD19.00 -21.7% | 2 qtrs — |
| 38 | BELVEDERE TRADING LLC | — -100.0 (-100.0%) | — -1.9K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 39 | CITIGROUP INC | — -2.6K (-100.0%) | — -50.4K (-100.0%) | 0.00% -0.030 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 40 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | — -3.0 (-100.0%) | — -58.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 41 | US BANCORP \DE\ | — -12.0 (-100.0%) | — -231.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 42 | HUDSON BAY CAPITAL MANAGEMENT LP | — -125.0K (-100.0%) | — -2.4M (-100.0%) | 0.00% -1.430 pp | 0.00% -0.008 pp | USD— | 2 qtrs SOLD |
| 43 | CENTIVA CAPITAL, LP | — -25.0K (-100.0%) | — -481.0K (-100.0%) | 0.00% -0.286 pp | 0.00% -0.005 pp | USD— | 2 qtrs SOLD |
| 44 | J. GOLDMAN & CO LP | — -61.9K (-100.0%) | — -1.2M (-100.0%) | 0.00% -0.708 pp | 0.00% -0.030 pp | USD— | 2 qtrs SOLD |
| 45 | JPMORGAN CHASE & CO | — -65.0 (-100.0%) | — -1.3K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 46 | ROYAL BANK OF CANADA | — -296.0 (-100.0%) | — -6.0K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 18 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 155.1K | 0.60% |
| 2 | WisdomTree U.S. SmallCap Fund EES | 0.01% | 60.9K | 0.38% |
| 3 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.00% | 78.8K | 0.34% |
| 4 | Schwab U.S. Small-Cap ETF SCHA | 0.00% | 189.4K | 0.03% |
| 5 | U.S. Micro Cap Portfolio ETF DFMC | 0.00% | 52.7K | 0.43% |
| 6 | Vanguard Extended Market ETF VXF | 0.00% | 542.7K | 0.05% |
| 7 | Avantis U.S. Small Cap Value ETF AVUV | 0.00% | 153.4K | 0.25% |
| 8 | Avantis U.S. Small Cap Equity ETF AVSC | 0.00% | 6.1K | 0.25% |
| 9 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 3.2K | 0.03% |
| 10 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 648.68 | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.67
Neutral
Ratio by volume
3.00
Bullish
Buys
8
Sells
12
Shares acquired
271.4K
Shares disposed
1.9K
Cash buys
—
Cash sales
4.00
Net activity
+269,498
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Thorell Marella | Officer | A-Award | A | Stock Option (right to buy) | 22,500 | 9.13 | 205.4K | 22,500 | D | ↗ |
| 2026-03-04 | Kender Richard N | Director / Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 9.13 | 1.37M | 150,000 | D | ↗ |
| 2026-03-04 | Henn Matthew R | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 9.13 | 684.8K | 75,000 | D | ↗ |
| 2026-03-04 | DesRosier Thomas | Officer | A-Award | A | Stock Option (right to buy) | 22,500 | 9.13 | 205.4K | 22,500 | D | ↗ |
| 2026-03-04 | Brady Kelly | Officer | A-Award | A | Stock Option (right to buy) | 56,250 | 9.13 | 513.6K | 56,250 | D | ↗ |
| 2026-03-02 | Brady Kelly | Officer | — | — | Stock Option (right to buy) | 1,430 | 23.00 | 32.9K | 0 | D | ↗ |
| 2026-02-15 | Young Teresa L. | Officer | M-Exempt | D | Restricted Stock Units | 133 | 0.00 | — | 531 | D | ↗ |
| 2026-02-15 | Shaff Eric D. | Director | M-Exempt | D | Restricted Stock Units | 391 | 0.00 | — | 1,564 | D | ↗ |
| 2026-02-15 | Henn Matthew R | Officer | M-Exempt | D | Restricted Stock Units | 141 | 0.00 | — | 563 | D | ↗ |
| 2026-02-15 | DesRosier Thomas | Officer | M-Exempt | D | Restricted Stock Units | 133 | 0.00 | — | 531 | D | ↗ |
| 2025-11-15 | Young Teresa L. | Officer | M-Exempt | D | Restricted Stock Units | 3,998 | 0.00 | — | 0 | D | ↗ |
| 2025-11-15 | Shaff Eric D. | Director | M-Exempt | D | Restricted Stock Units | 390 | 0.00 | — | 1,954 | D | ↗ |
| 2025-11-15 | Henn Matthew R | Officer | M-Exempt | A | Common Stock | 98 | 0.00 | — | 8,784 | D | ↗ |
| 2025-11-15 | DesRosier Thomas | Officer | S-Sale | D | Common Stock | 76 | 17.30 | 1.3K | 7,623 | D | ↗ |
| 2025-09-26 | Young Teresa L. | Officer | A-Award | A | Restricted Stock Units | 3,998 | 0.00 | — | 3,998 | D | ↗ |
| 2025-09-26 | Henn Matthew R | Officer | A-Award | A | Restricted Stock Units | 3,998 | 0.00 | — | 3,998 | D | ↗ |
| 2025-08-18 | Young Teresa L. | Officer | S-Sale | D | Common Stock | 59 | 16.65 | 982.35 | 5,215 | D | ↗ |
| 2025-08-18 | Shaff Eric D. | Director | S-Sale | D | Common Stock | 217 | 16.65 | 3.6K | 10,609 | D | ↗ |
| 2025-08-18 | Henn Matthew R | Officer | S-Sale | D | Common Stock | 73 | 16.65 | 1.2K | 4,548 | D | ↗ |
| 2025-08-18 | DesRosier Thomas | Officer | S-Sale | D | Common Stock | 76 | 16.65 | 1.3K | 7,455 | D | ↗ |
| 2025-08-15 | Young Teresa L. | Officer | M-Exempt | D | Restricted Stock Units | 133 | 0.00 | — | 796 | D | ↗ |
| 2025-08-15 | Shaff Eric D. | Director | M-Exempt | A | Common Stock | 391 | 0.00 | — | 10,493 | D | ↗ |
| 2025-08-15 | Henn Matthew R | Officer | M-Exempt | D | Restricted Stock Units | 97 | 0.00 | — | 976 | D | ↗ |
| 2025-08-15 | DesRosier Thomas | Officer | M-Exempt | D | Restricted Stock Units | 133 | 0.00 | — | 796 | D | ↗ |
| 2025-08-05 | Rosiello Robert L. | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 14.28 | 142.8K | 10,000 | D | ↗ |
| 2025-07-01 | Fraser Claire | Director | A-Award | A | Stock Option (right to buy) | 6,452 | 10.71 | 69.1K | 6,452 | D | ↗ |
| 2025-07-01 | Berenson Stephen | Director | A-Award | A | Stock Option (right to buy) | 11,470 | 10.71 | 122.8K | 11,470 | D | ↗ |
| 2025-07-01 | Ausiello Dennis A | Director | A-Award | A | Stock Option (right to buy) | 6,452 | 10.71 | 69.1K | 6,452 | D | ↗ |
| 2025-05-16 | Young Teresa L. | Officer | S-Sale | D | Common Stock | 63 | 7.28 | 458.64 | 5,044 | D | ↗ |
| 2025-05-16 | Shaff Eric D. | Director / Officer | S-Sale | D | Common Stock | 220 | 7.28 | 1.6K | 10,102 | D | ↗ |
| 2025-05-16 | Henn Matthew R | Officer | S-Sale | D | Common Stock | 77 | 7.28 | 560.56 | 4,383 | D | ↗ |
| 2025-05-15 | Young Teresa L. | Officer | M-Exempt | D | Restricted Stock Units | 133 | 0.00 | — | 929 | D | ↗ |
| 2025-05-15 | Shaff Eric D. | Director / Officer | M-Exempt | D | Restricted Stock Units | 390 | 0.00 | — | 2,735 | D | ↗ |
| 2025-05-15 | Henn Matthew R | Officer | M-Exempt | D | Restricted Stock Units | 140 | 0.00 | — | 985 | D | ↗ |
| 2025-05-15 | DesRosier Thomas | Officer | S-Sale | D | Common Stock | 79 | 7.28 | 575.12 | 7,287 | D | ↗ |
| 2025-04-10 | Kender Richard N | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.58 | 58.0K | 100,000 | D | ↗ |
| 2025-04-10 | Graves Kurt | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.58 | 58.0K | 100,000 | D | ↗ |
| 2025-04-10 | Fraser Claire | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.58 | 58.0K | 100,000 | D | ↗ |
| 2025-04-10 | Biondi Paul | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.58 | 58.0K | 100,000 | D | ↗ |
| 2025-04-10 | Berenson Stephen | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.58 | 58.0K | 100,000 | D | ↗ |
| 2025-04-10 | Ausiello Dennis A | Director | A-Award | A | Stock Option (right to buy) | 100,000 | 0.58 | 58.0K | 100,000 | D | ↗ |
| 2025-02-18 | von Moltke Lisa | Officer | S-Sale | D | Common Stock | 4,416 | 0.81 | 3.6K | 39,875 | D | ↗ |
| 2025-02-18 | Young Teresa L. | Officer | S-Sale | D | Common Stock | 3,338 | 0.81 | 2.7K | 97,536 | D | ↗ |
| 2025-02-18 | Shaff Eric D. | Director / Officer | S-Sale | D | Common Stock | 12,726 | 0.81 | 10.3K | 192,039 | D | ↗ |
| 2025-02-18 | Henn Matthew R. | Officer | S-Sale | D | Common Stock | 3,953 | 0.81 | 3.2K | 84,443 | D | ↗ |
| 2025-02-18 | DesRosier Thomas | Officer | S-Sale | D | Common Stock | 4,300 | 0.81 | 3.5K | 142,456 | D | ↗ |
| 2025-02-15 | von Moltke Lisa | Officer | M-Exempt | D | Restricted Stock Units | 2,969 | 0.00 | — | 23,750 | D | ↗ |
| 2025-02-15 | Young Teresa L. | Officer | M-Exempt | A | Common Stock | 2,657 | 0.00 | — | 93,061 | D | ↗ |
| 2025-02-15 | Shaff Eric D. | Director / Officer | M-Exempt | D | Restricted Stock Units | 26,563 | 0.00 | — | 79,687 | D | ↗ |
| 2025-02-15 | Henn Matthew R. | Officer | M-Exempt | A | Common Stock | 7,813 | 0.00 | — | 88,396 | D | ↗ |
| 2025-02-15 | DesRosier Thomas | Officer | M-Exempt | D | Restricted Stock Units | 2,657 | 0.00 | — | 21,250 | D | ↗ |
| 2025-02-07 | von Moltke Lisa | Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 0.78 | 508.3K | 650,000 | D | ↗ |
| 2025-02-07 | Young Teresa L. | Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 0.78 | 508.3K | 650,000 | D | ↗ |
| 2025-02-07 | Thorell Marella | Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 0.78 | 508.3K | 650,000 | D | ↗ |
| 2025-02-07 | Shaff Eric D. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,950,000 | 0.78 | 1.52M | 1,950,000 | D | ↗ |
| 2025-02-07 | Henn Matthew R. | Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 0.78 | 508.3K | 650,000 | D | ↗ |
| 2025-02-07 | DesRosier Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 0.78 | 508.3K | 650,000 | D | ↗ |
| 2025-02-04 | Woerle Hans-Juergen | Director | A-Award | A | Stock Option (right to buy) | 120,000 | 0.81 | 96.7K | 120,000 | D | ↗ |
| 2024-11-18 | von Moltke Lisa | Officer | S-Sale | D | Common Stock | 977 | 0.54 | 528.26 | 32,415 | D | ↗ |
| 2024-11-18 | Young Teresa L. | Officer | S-Sale | D | Common Stock | 735 | 0.54 | 397.64 | 90,404 | D | ↗ |
| 2024-11-18 | Shaff Eric D. | Director / Officer | S-Sale | D | Common Stock | 2,505 | 0.54 | 1.4K | 170,389 | D | ↗ |
| 2024-11-18 | Henn Matthew R. | Officer | S-Sale | D | Common Stock | 927 | 0.54 | 501.23 | 77,770 | D | ↗ |
| 2024-11-18 | DesRosier Thomas | Officer | S-Sale | D | Common Stock | 878 | 0.54 | 474.73 | 135,192 | D | ↗ |
| 2024-11-15 | von Moltke Lisa | Officer | M-Exempt | D | Restricted Stock Units | 2,969 | 0.00 | — | 26,719 | D | ↗ |
| 2024-11-15 | Young Teresa L. | Officer | M-Exempt | A | Common Stock | 2,656 | 0.00 | — | 91,139 | D | ↗ |
| 2024-11-15 | Shaff Eric D. | Director / Officer | M-Exempt | D | Restricted Stock Units | 7,812 | 0.00 | — | 70,313 | D | ↗ |
| 2024-11-15 | Henn Matthew R. | Officer | M-Exempt | A | Common Stock | 2,812 | 0.00 | — | 78,697 | D | ↗ |
| 2024-11-15 | DesRosier Thomas | Officer | M-Exempt | D | Restricted Stock Units | 2,656 | 0.00 | — | 23,907 | D | ↗ |
| 2024-10-28 | von Moltke Lisa | Officer | S-Sale | D | Common Stock | 4,334 | 0.69 | 3.0K | 30,423 | D | ↗ |
| 2024-10-28 | Young Teresa L. | Officer | S-Sale | D | Common Stock | 2,983 | 0.69 | 2.1K | 88,483 | D | ↗ |
| 2024-10-28 | Shaff Eric D. | Director / Officer | S-Sale | D | Common Stock | 8,748 | 0.69 | 6.0K | 165,082 | D | ↗ |
| 2024-10-28 | Henn Matthew R. | Officer | S-Sale | D | Common Stock | 3,984 | 0.69 | 2.7K | 75,885 | D | ↗ |
| 2024-10-28 | DesRosier Thomas | Officer | S-Sale | D | Common Stock | 4,259 | 0.69 | 2.9K | 133,414 | D | ↗ |
| 2024-10-27 | von Moltke Lisa | Officer | M-Exempt | D | Restricted Stock Units | 13,744 | 0.00 | — | 0 | D | ↗ |
| 2024-10-27 | Young Teresa L. | Officer | M-Exempt | A | Common Stock | 11,360 | 0.00 | — | 91,466 | D | ↗ |
| 2024-10-27 | Shaff Eric D. | Director / Officer | M-Exempt | D | Restricted Stock Units | 27,837 | 0.00 | — | 0 | D | ↗ |
| 2024-10-27 | Henn Matthew R. | Officer | M-Exempt | A | Common Stock | 12,622 | 0.00 | — | 79,869 | D | ↗ |
| 2024-10-27 | DesRosier Thomas | Officer | M-Exempt | D | Restricted Stock Units | 13,500 | 0.00 | — | 0 | D | ↗ |
| 2024-09-30 | NESTLE SA | 10% Owner | — | — | Common Stock, par value $0.001 | 0 | 0.00 | — | 21,879,753 | I | ↗ |
| 2024-08-16 | von Moltke Lisa | Officer | S-Sale | D | Common Stock | 973 | 0.84 | 817.32 | 21,013 | — | ↗ |
| 2024-08-16 | Young Teresa L. | Officer | S-Sale | D | Common Stock | 728 | 0.84 | 611.52 | 80,106 | — | ↗ |
| 2024-08-16 | Shaff Eric D. | Director / Officer | S-Sale | D | Common Stock | 2,518 | 0.84 | 2.1K | 145,993 | — | ↗ |
| 2024-08-16 | Henn Matthew R. | Officer | S-Sale | D | Common Stock | 923 | 0.84 | 775.32 | 67,247 | — | ↗ |
| 2024-08-16 | Ege David S. | Officer | S-Sale | D | Common Stock | 1,128 | 0.84 | 947.52 | 77,575 | — | ↗ |
| 2024-08-16 | DesRosier Thomas | Officer | S-Sale | D | Common Stock | 873 | 0.84 | 733.32 | 124,173 | — | ↗ |
| 2024-08-15 | von Moltke Lisa | Officer | M-Exempt | A | Common Stock | 2,969 | 0.00 | — | 21,986 | — | ↗ |
| 2024-08-15 | Young Teresa L. | Officer | M-Exempt | D | Restricted Stock Units | 2,656 | 0.00 | — | 26,563 | — | ↗ |
| 2024-08-15 | Shaff Eric D. | Director / Officer | M-Exempt | D | Restricted Stock Units | 7,813 | 0.00 | — | 78,125 | — | ↗ |
| 2024-08-15 | Henn Matthew R. | Officer | M-Exempt | D | Restricted Stock Units | 2,813 | 0.00 | — | 28,125 | — | ↗ |
| 2024-08-15 | Ege David S. | Officer | M-Exempt | D | Restricted Stock Units | 2,969 | 0.00 | — | 29,688 | — | ↗ |
| 2024-08-15 | DesRosier Thomas | Officer | M-Exempt | D | Restricted Stock Units | 2,656 | 0.00 | — | 26,563 | — | ↗ |
| 2024-08-05 | Young Teresa L. | Officer | S-Sale | D | Common Stock | 24,480 | 1.08 | 26.5K | 78,178 | — | ↗ |
| 2024-08-03 | Young Teresa L. | Officer | M-Exempt | A | Common Stock | 85,000 | 0.00 | — | 102,658 | — | ↗ |
| 2024-07-01 | Graves Kurt | Director | A-Award | A | Stock Option (right to buy) | 64,564 | 0.72 | 46.5K | 64,564 | — | ↗ |
| 2024-07-01 | Berenson Stephen | Director | A-Award | A | Stock Option (Right to Buy) | 114,782 | 0.72 | 82.6K | 114,782 | — | ↗ |
| 2024-07-01 | Ausiello Dennis A | Director | A-Award | A | Stock Option (right to buy) | 64,564 | 0.72 | 46.5K | 64,564 | — | ↗ |
| 2024-05-15 | von Moltke Lisa | Officer | M-Exempt | A | Common Stock | 2,968 | 0.00 | — | 19,956 | — | ↗ |
| 2024-05-15 | Young Teresa L. | Officer | S-Sale | D | Common Stock | 703 | 0.94 | 660.82 | 17,658 | — | ↗ |
| 2024-05-15 | Shaff Eric D. | Director / Officer | M-Exempt | D | Restricted Stock Units | 7,812 | 0.00 | — | 85,938 | — | ↗ |
| 2024-05-15 | Henn Matthew R. | Officer | M-Exempt | D | Restricted Stock Units | 2,812 | 0.00 | — | 30,938 | — | ↗ |
| 2024-05-15 | Ege David S. | Officer | M-Exempt | D | Restricted Stock Units | 2,968 | 0.00 | — | 32,657 | — | ↗ |
| 2024-05-15 | DesRosier Thomas | Officer | M-Exempt | A | Common Stock | 2,656 | 0.00 | — | 123,233 | — | ↗ |
| 2024-04-04 | Kender Richard N | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 0.76 | 45.6K | 60,000 | — | ↗ |
| 2024-04-04 | Graves Kurt | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 0.76 | 45.6K | 60,000 | — | ↗ |
| 2024-04-04 | Fraser Claire | Director | A-Award | A | Stock Option (right to buy | 60,000 | 0.76 | 45.6K | 60,000 | — | ↗ |
| 2024-04-04 | Dere Willard H | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 0.76 | 45.6K | 60,000 | — | ↗ |
| 2024-04-04 | Biondi Paul | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.76 | 45.6K | 60,000 | — | ↗ |
| 2024-04-04 | Berenson Stephen | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.76 | 45.6K | 60,000 | — | ↗ |
| 2024-04-04 | Ausiello Dennis A | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 0.76 | 45.6K | 60,000 | — | ↗ |
| 2024-03-25 | Thorell Marella | Officer | A-Award | A | Stock Options (right to buy) | 700,000 | 0.79 | 553.0K | 700,000 | — | ↗ |
| 2024-02-16 | von Moltke Lisa | Officer | S-Sale | D | Common Stock | 4,400 | 1.08 | 4.8K | 16,988 | — | ↗ |
| 2024-02-16 | Young Teresa L. | Officer | S-Sale | D | Common Stock | 3,374 | 1.08 | 3.6K | 15,705 | — | ↗ |
| 2024-02-16 | Shaff Eric D. | Director / Officer | S-Sale | D | Common Stock | 11,549 | 1.08 | 12.5K | 135,321 | — | ↗ |
| 2024-02-16 | Henn Matthew R. | Officer | S-Sale | D | Common Stock | 4,170 | 1.08 | 4.5K | 63,436 | — | ↗ |
| 2024-02-16 | Ege David S. | Officer | S-Sale | D | Common Stock | 5,010 | 1.08 | 5.4K | 73,856 | — | ↗ |
| 2024-02-16 | DesRosier Thomas | Officer | S-Sale | D | Common Stock | 3,939 | 1.08 | 4.3K | 120,577 | — | ↗ |
| 2024-02-16 | Arkowitz David | Officer | S-Sale | D | Common Stock | 3,939 | 1.08 | 4.3K | 182,442 | — | ↗ |
| 2024-02-15 | von Moltke Lisa | Officer | M-Exempt | D | Restricted Stock Units | 11,875 | 0.00 | — | 35,625 | — | ↗ |
| 2024-02-15 | Young Teresa L. | Officer | M-Exempt | A | Common Stock | 10,625 | 0.00 | — | 19,079 | — | ↗ |
| 2024-02-15 | Shaff Eric D. | Director / Officer | M-Exempt | D | Restricted Stock Units | 31,250 | 0.00 | — | 93,750 | — | ↗ |
| 2024-02-15 | Henn Matthew R. | Officer | M-Exempt | A | Common Stock | 11,250 | 0.00 | — | 67,606 | — | ↗ |
| 2024-02-15 | Ege David S. | Officer | M-Exempt | A | Common Stock | 11,875 | 0.00 | — | 78,866 | — | ↗ |
| 2024-02-15 | DesRosier Thomas | Officer | M-Exempt | A | Common Stock | 10,625 | 0.00 | — | 124,516 | — | ↗ |
| 2024-02-15 | Arkowitz David | Officer | M-Exempt | D | Restricted Stock Units | 10,625 | 0.00 | — | 31,875 | — | ↗ |
| 2024-02-14 | von Moltke Lisa | Officer | A-Award | A | Restricted Stock Units | 35,625 | 0.00 | — | 35,625 | — | ↗ |
| 2024-02-14 | Young Teresa L. | Officer | A-Award | A | Stock Option (Right to Buy) | 287,905 | 1.10 | 316.7K | 287,905 | — | ↗ |
| 2024-02-14 | Shaff Eric D. | Director / Officer | A-Award | A | Restricted Stock Units | 106,250 | 0.00 | — | 106,250 | — | ↗ |
| 2024-02-14 | Henn Matthew R. | Officer | A-Award | A | Stock Option (Right to Buy) | 287,905 | 1.10 | 316.7K | 287,905 | — | ↗ |
| 2024-02-14 | Ege David S. | Officer | A-Award | A | Restricted Stock Units | 31,250 | 0.00 | — | 31,250 | — | ↗ |
| 2024-02-14 | DesRosier Thomas | Officer | A-Award | A | Restricted Stock Units | 35,625 | 0.00 | — | 35,625 | — | ↗ |
| 2024-02-14 | Arkowitz David | Officer | A-Award | A | Stock Option (Right to Buy) | 287,905 | 1.10 | 316.7K | 287,905 | — | ↗ |
| 2023-10-30 | von Moltke Lisa | Officer | S-Sale | D | Common Stock | 4,232 | 1.35 | 5.7K | 9,513 | — | ↗ |
| 2023-10-30 | Young Teresa L. | Officer | S-Sale | D | Common Stock | 2,907 | 1.35 | 3.9K | 8,454 | — | ↗ |
| 2023-10-30 | Shaff Eric D. | Director / Officer | S-Sale | D | Common Stock | 8,552 | 1.35 | 11.5K | 115,620 | — | ↗ |
| 2023-10-30 | Henn Matthew R. | Officer | S-Sale | D | Common Stock | 3,886 | 1.35 | 5.2K | 56,356 | — | ↗ |
| 2023-10-30 | Ege David S. | Officer | S-Sale | D | Common Stock | 4,066 | 1.35 | 5.5K | 66,991 | — | ↗ |
| 2023-10-30 | DesRosier Thomas | Officer | S-Sale | D | Common Stock | 4,156 | 1.35 | 5.6K | 113,891 | — | ↗ |
| 2023-10-30 | Cloghessy Paula | Officer | S-Sale | D | Common Stock | 2,904 | 1.35 | 3.9K | 45,684 | — | ↗ |
| 2023-10-30 | Arkowitz David | Officer | S-Sale | D | Common Stock | 4,066 | 1.35 | 5.5K | 175,756 | — | ↗ |
| 2023-10-27 | von Moltke Lisa | Officer | M-Exempt | A | Common Stock | 13,745 | 0.00 | — | 13,745 | — | ↗ |
| 2023-10-27 | Young Teresa L. | Officer | M-Exempt | D | Restricted Stock Units | 11,361 | 0.00 | — | 11,360 | — | ↗ |
| 2023-10-27 | Shaff Eric D. | Director / Officer | M-Exempt | A | Common Stock | 27,838 | 0.00 | — | 124,172 | — | ↗ |
| 2023-10-27 | Henn Matthew R. | Officer | M-Exempt | A | Common Stock | 12,623 | 0.00 | — | 60,242 | — | ↗ |
| 2023-10-27 | Ege David S. | Officer | M-Exempt | A | Common Stock | 11,361 | 0.00 | — | 71,057 | — | ↗ |
| 2023-10-27 | DesRosier Thomas | Officer | M-Exempt | D | Restricted Stock Units | 13,501 | 0.00 | — | 13,500 | — | ↗ |
| 2023-10-27 | Cloghessy Paula | Officer | M-Exempt | D | Restricted Stock Units | 9,418 | 0.00 | — | 9,417 | — | ↗ |
| 2023-10-27 | Arkowitz David | Officer | M-Exempt | D | Restricted Stock Units | 13,209 | 0.00 | — | 13,209 | — | ↗ |
| 2023-06-22 | Kender Richard N | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 5.46 | 191.1K | 35,000 | — | ↗ |
| 2023-06-22 | Graves Kurt | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 5.46 | 191.1K | 35,000 | — | ↗ |
| 2023-06-22 | Fraser Claire | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 5.46 | 191.1K | 35,000 | — | ↗ |
| 2023-06-22 | Dere Willard H | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 5.46 | 191.1K | 35,000 | — | ↗ |
| 2023-06-22 | Biondi Paul | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 5.46 | 191.1K | 35,000 | — | ↗ |
| 2023-06-22 | Berenson Stephen | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 5.46 | 191.1K | 35,000 | — | ↗ |
| 2023-06-22 | Behar Gregory | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 5.46 | 191.1K | 35,000 | — | ↗ |
| 2023-06-22 | Ausiello Dennis A | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 5.46 | 191.1K | 35,000 | — | ↗ |
| 2023-04-28 | Ege David S. | Officer | S-Sale | D | Common stock | 7,038 | 5.19 | 36.5K | 59,696 | — | ↗ |
| 2023-04-27 | von Moltke Lisa | Officer | A-Award | A | Restricted Stock Units | 27,489 | 0.00 | — | 27,489 | — | ↗ |
| 2023-04-27 | Young Teresa L. | Officer | A-Award | A | Restricted Stock Units | 22,721 | 0.00 | — | 22,721 | — | ↗ |
| 2023-04-27 | Shaff Eric D. | Director / Officer | A-Award | A | Restricted Stock Units | 55,675 | 0.00 | — | 55,675 | — | ↗ |
| 2023-04-27 | Henn Matthew R. | Officer | A-Award | A | Stock Option (Right to Buy) | 35,000 | 10.84 | 379.4K | 70,000 | — | ↗ |
| 2023-04-27 | Ege David S. | Officer | A-Award | A | Common stock | 20,000 | 0.00 | — | 66,734 | — | ↗ |
| 2023-04-27 | DesRosier Thomas | Officer | A-Award | A | Restricted Stock Units | 27,001 | 0.00 | — | 27,001 | — | ↗ |
| 2023-04-27 | Cloghessy Paula | Officer | A-Award | A | Restricted Stock Units | 18,835 | 0.00 | — | 18,835 | — | ↗ |
| 2023-04-27 | Arkowitz David | Officer | A-Award | A | Common stock | 42,500 | 0.00 | — | 166,613 | — | ↗ |
| 2023-02-03 | von Moltke Lisa | Officer | A-Award | A | Restricted Stock Units | 47,500 | 0.00 | — | 47,500 | — | ↗ |
| 2023-02-03 | Young Teresa L. | Officer | A-Award | A | Restricted Stock Units | 42,500 | 0.00 | — | 42,500 | — | ↗ |
| 2023-02-03 | Shaff Eric D. | Director / Officer | A-Award | A | Restricted Stock Units | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2023-02-03 | Henn Matthew R. | Officer | A-Award | A | Restricted Stock Units | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2023-02-03 | Ege David S. | Officer | A-Award | A | Stock Option (Right to Buy) | 95,000 | 5.50 | 522.5K | 95,000 | — | ↗ |
| 2023-02-03 | DesRosier Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 85,000 | 5.50 | 467.5K | 85,000 | — | ↗ |
| 2023-02-03 | Cloghessy Paula | Officer | A-Award | A | Restricted Stock Units | 47,500 | 0.00 | — | 47,500 | — | ↗ |
| 2023-02-03 | Arkowitz David | Officer | A-Award | A | Restricted Stock Units | 42,500 | 0.00 | — | 42,500 | — | ↗ |
| 2023-01-04 | Fraser Claire | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-10-31 | Ege David S. | Officer | S-Sale | D | Common stock | 5,012 | 7.93 | 39.7K | 46,734 | — | ↗ |
| 2022-10-27 | Ege David S. | Officer | A-Award | A | Common stock | 20,000 | 0.00 | — | 51,746 | — | ↗ |
| 2022-10-27 | Arkowitz David | Officer | A-Award | A | Common stock | 42,500 | 0.00 | — | 112,992 | — | ↗ |
| 2022-07-05 | Zausner Meryl | Director | A-Award | A | COMMON STOCK | 31,746 | 3.15 | 100.0K | 31,746 | — | ↗ |
| 2022-07-05 | Shaff Eric D. | Officer | A-Award | A | COMMON STOCK | 63,492 | 3.15 | 200.0K | 96,334 | — | ↗ |
| 2022-07-05 | Nutritional Health LTP Fund General Partner LLC | 10% Owner | P-Purchase | A | Common Stock | 2,912,748 | 3.15 | 9.18M | 5,875,711 | — | ↗ |
| 2022-07-05 | Kender Richard N | Director | A-Award | A | COMMON STOCK | 63,492 | 3.15 | 200.0K | 63,492 | — | ↗ |
| 2022-07-05 | Henn Matthew R. | Officer | A-Award | A | COMMON STOCK | 47,619 | 3.15 | 150.0K | 47,619 | — | ↗ |
| 2022-07-05 | Flagship Pioneering Fund VII General Partner LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 5,825,495 | — | ↗ |
| 2022-07-05 | Ege David S. | Officer | A-Award | A | COMMON STOCK | 31,746 | 3.15 | 100.0K | 31,746 | — | ↗ |
| 2022-07-05 | DesRosier Thomas | Officer | A-Award | A | COMMON STOCK | 63,492 | 3.15 | 200.0K | 104,546 | — | ↗ |
| 2022-07-05 | Dere Willard H | Director | A-Award | A | COMMON STOCK | 31,746 | 3.15 | 100.0K | 31,746 | — | ↗ |
| 2022-07-05 | Cloghessy Paula | Officer | A-Award | A | COMMON STOCK | 31,746 | 3.15 | 100.0K | 31,746 | — | ↗ |
| 2022-07-05 | Biondi Paul | Director | A-Award | A | COMMON STOCK | 47,619 | 3.15 | 150.0K | 47,619 | — | ↗ |
| 2022-07-05 | Arkowitz David | Officer | A-Award | A | COMMON STOCK | 63,492 | 3.15 | 200.0K | 65,492 | — | ↗ |
| 2022-07-05 | AFEYAN NOUBAR | Director | P-Purchase | A | Common Stock | 2,912,748 | 3.15 | 9.18M | 5,875,711 | — | ↗ |
| 2022-06-22 | Zausner Meryl | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 3.22 | 112.7K | 35,000 | D | ↗ |
| 2022-06-22 | Kender Richard N | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-06-22 | Graves Kurt | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-06-22 | Dere Willard H | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-06-22 | Biondi Paul | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 3.22 | 112.7K | 35,000 | — | ↗ |
| 2022-06-22 | Berenson Stephen | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-06-22 | Behar Gregory | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 3.22 | 112.7K | 35,000 | — | ↗ |
| 2022-06-22 | Ausiello Dennis A | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-06-15 | Arkowitz David | Officer | M-Exempt | A | Common stock | 5,000 | 0.00 | — | 70,492 | — | ↗ |
| 2022-02-07 | Cloghessy Paula | Officer | A-Award | A | Stock Options (right to buy) | 190,000 | 7.60 | 1.44M | 190,000 | — | ↗ |
| 2022-02-04 | von Moltke Lisa | Officer | A-Award | A | Stock Option (Right to Buy) | 175,000 | 7.38 | 1.29M | 175,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-9.1K
Shares Outstanding
9.63M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Eric D. Shaff Former President and Chief Executive Officer | 408.3K | — | — | 1.34M | — | 28.3K | 1.78M | 75.41% | ↗ |
| 2 | 2025 | Thomas J. DesRosier Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer | 512.9K | 166.7K | — | 446.3K | — | 10.2K | 1.14M | 39.29% | ↗ |
| 3 | 2025 | Marella Thorell Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Financial Officer | 494.4K | 166.7K | — | 446.3K | — | 6.0K | 1.11M | 40.08% | ↗ |
| 4 | 2025 | Teresa L. Young, Ph.D. Former Executive Vice President and Chief Commercial and Strategy Officer | 489.3K | — | 75.7K | 446.3K | — | 10.2K | 1.02M | 51.10% | ↗ |
| 5 | 2025 | Matthew Henn, Ph.D. President and Chief Scientific Officer | 489.3K | — | 75.7K | 446.3K | — | 3.1K | 1.01M | 51.46% | ↗ |
| 6 | 2024 | Eric D. Shaff President and Chief Executive Officer | 685.0K | — | 116.9K | 1.46M | 411.0K | 9.3K | 2.68M | 58.79% | ↗ |
| 7 | 2024 | Eric D. Shaff Former President and Chief Executive Officer | 685.0K | — | 116.9K | 1.46M | 411.0K | 9.3K | 2.68M | 58.79% | ↗ |
| 8 | 2024 | Lisa von Moltke, M.D. Executive Vice President and Chief Medical Officer | 515.0K | — | 39.2K | 502.2K | 206.0K | 8.0K | 1.27M | 42.62% | ↗ |
| 9 | 2024 | Thomas J. DesRosier Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer | 498.0K | — | 39.2K | 502.2K | 199.2K | 9.9K | 1.25M | 43.36% | ↗ |
| 10 | 2024 | Thomas J. DesRosier Executive Vice President and Chief Legal Officer | 498.0K | — | 39.2K | 502.2K | 199.2K | 9.9K | 1.25M | 43.36% | ↗ |
| 11 | 2023 | Eric D. Shaff President and Chief Executive Officer | 685.0K | — | 993.7K | 1.14M | 328.8K | 9.9K | 3.16M | 67.59% | ↗ |
| 12 | 2023 | Teresa L. Young, Ph.D. Executive Vice President, Chief Commercial and Strategy Officer | 437.0K | — | 826.2K | 387.9K | 167.8K | 1.5K | 1.82M | 66.69% | ↗ |
| 13 | 2023 | Lisa von Moltke, M.D. Executive Vice President and Chief Medical Officer | 515.0K | — | 412.4K | 433.6K | 201.9K | 8.3K | 1.57M | 53.85% | ↗ |
| 14 | 2022 | Eric D. Shaff President and Chief Executive Officer | 661.6K | — | — | 2.94M | 397.0K | 9.1K | 4.01M | 73.35% | ↗ |
| 15 | 2022 | David Arkowitz Executive Vice President, Chief Financial Officer and Head of Business Development | 470.9K | — | — | 1.12M | 190.0K | 9.1K | 1.79M | 62.50% | ↗ |
| 16 | 2022 | Lisa von Moltke, M.D. Executive Vice President and Chief Medical Officer | 490.0K | — | — | 1.03M | 208.0K | 8.1K | 1.73M | 59.29% | ↗ |
| 17 | 2022 | Matthew Henn, Ph.D. Executive Vice President and Chief Scientific Officer | 450.0K | — | — | 1.03M | 185.0K | 8.8K | 1.67M | 61.50% | ↗ |
| 18 | 2022 | Paula A. Cloghessy Executive Vice President and Chief People Officer | 338.2K | — | — | 1.15M | 136.0K | 8.8K | 1.63M | 70.42% | ↗ |
| 19 | 2021 | Eric D. Shaff President and Chief Executive Officer | 625.4K | — | — | 8.76M | 319.0K | 8.7K | 9.71M | 90.19% | ↗ |
| 20 | 2021 | David Arkowitz Executive Vice President, Chief Financial Officer and Head of Business Development | 265.4K | 50.0K | 916.1K | 3.90M | 94.0K | 4.4K | 5.23M | 92.08% | ↗ |
| 21 | 2021 | Matthew Henn, Ph.D. Executive Vice President and Chief Scientific Officer | 430.0K | — | — | 2.96M | 153.1K | 8.7K | 3.55M | 83.34% | ↗ |
| 22 | 2020 | David S. Ege, Ph.D. Executive Vice President and Chief Technology Officer | 76.9K | 65.0K | — | 5.18M | — | 785.00 | 5.32M | 97.32% | ↗ |
| 23 | 2020 | Eric D. Shaff President and Chief Executive Officer | 590.0K | — | — | 2.05M | 486.8K | 8.6K | 3.14M | 65.39% | ↗ |
| 24 | 2020 | Thomas J. DesRosier Executive Vice President, Chief Legal Officer and Secretary | 450.0K | — | — | 717.7K | 261.0K | 8.6K | 1.44M | 49.94% | ↗ |
| 25 | 2019 | Eric D. Shaff President and Chief Executive Officer | 540.0K | — | — | 1.23M | 253.0K | 8.4K | 2.03M | 60.57% | ↗ |
| 26 | 2019 | Thomas J. DesRosier Chief Legal Officer, Executive Vice President, and Secretary | 428.3K | — | — | 379.6K | 161.0K | 8.4K | 977.3K | 38.84% | ↗ |
| 27 | 2019 | Thomas J. DesRosier Executive Vice President, Chief Legal Officer and Secretary | 428.3K | — | — | 379.6K | 161.0K | 8.4K | 977.3K | 38.84% | ↗ |
| 28 | 2019 | Matthew R. Henn, Ph.D. Executive Vice President and Chief Scientific Officer | 385.0K | — | — | 329.1K | 137.0K | 8.4K | 859.5K | 38.29% | ↗ |
| 29 | 2019 | Roger J. Pomerantz, M.D. Former President and Chief Executive Officer | 79.7K | — | — | 33.2K | — | 580.8K | 693.7K | 4.78% | ↗ |
| 30 | 2018 | Roger J. Pomerantz, M.D. Former President and Chief Executive Officer | 595.0K | — | — | 1.96M | 278.2K | 186.1K | 3.02M | 64.90% | ↗ |
| 31 | 2018 | Thomas J. DesRosier Chief Legal Officer, Executive Vice President, and Secretary | 413.8K | — | — | 1.27M | 149.0K | 8.3K | 1.84M | 68.95% | ↗ |
| 32 | 2018 | Eric D. Shaff Executive Vice President, Former Chief Operating and Financial Officer, and Treasurer | 435.0K | — | — | 845.5K | 158.3K | 8.3K | 1.45M | 58.43% | ↗ |
| 33 | 2018 | Eric D. Shaff President and Chief Executive Officer | 435.0K | — | — | 845.5K | 158.3K | 8.3K | 1.45M | 58.43% | ↗ |
| 34 | 2017 | Roger J. Pomerantz, M.D. President and Chief Executive Officer | 581.4K | — | — | 1.81M | 348.9K | 168.7K | 2.91M | 62.22% | ↗ |
| 35 | 2017 | Roger J. Pomerantz, M.D. Former President and Chief Executive Officer | 581.4K | — | — | 1.81M | 348.9K | 168.7K | 2.91M | 62.22% | ↗ |
| 36 | 2017 | Michele Trucksis, Ph.D. M.D. Executive Vice President and Chief Medical Officer | 427.3K | — | 370.9K | 693.4K | 198.3K | 6.1K | 1.70M | 62.78% | ↗ |
| 37 | 2017 | Eric D. Shaff Executive Vice President, Former Chief Operating and Financial Officer, and Treasurer | 377.1K | 3.0K | 395.6K | 728.1K | 175.0K | 6.8K | 1.69M | 66.66% | ↗ |
| 38 | 2017 | Eric Shaff Executive Vice President, Chief Operating and Financial Officer, and Treasurer | 377.1K | 3.0K | 395.6K | 728.1K | 175.0K | 6.8K | 1.69M | 66.66% | ↗ |
| 39 | 2016 | Roger J. Pomerantz, M.D. President and Chief Executive Officer | 564.5K | — | — | 3.29M | 225.8K | 175.8K | 4.26M | 77.30% | ↗ |
| 40 | 2016 | Wael Hashad Executive Vice President and Chief Commercial Officer | 338.9K | — | — | 2.43M | 109.5K | 29.6K | 2.91M | 83.58% | ↗ |
| 41 | 2016 | Thomas DesRosier Executive Vice President, Chief Legal Officer and Secretary | 243.8K | — | — | 2.20M | 125.6K | 5.9K | 2.58M | 85.44% | ↗ |
| 42 | 2015 | Michele Trucksis, Ph.D., M.D. Executive Vice President and Chief Medical Officer | 332.3K | 40.0K | — | 3.56M | 185.0K | — | 4.14M | 86.05% | ↗ |
| 43 | 2015 | Eric D. Shaff Executive Vice President and Chief Financial Officer | 312.8K | — | — | 1.29M | 170.4K | — | 1.77M | 72.74% | ↗ |
| 44 | 2015 | Roger J. Pomerantz, M.D. President and Chief Executive Officer | 455.6K | — | — | — | 348.1K | 74.4K | 878.2K | 0.00% | ↗ |
| 45 | 2014 | Roger J. Pomerantz, M.D. President and Chief Executive Officer | 247.9K | 233.8K | — | 6.57M | — | 69.4K | 7.12M | 92.26% | ↗ |
| 46 | 2014 | Eric D. Shaff Executive Vice President and Chief Financial Officer | 35.2K | 12.2K | — | 1.41M | — | — | 1.46M | 96.76% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas J. DesRosier | Executive VP, Chief Legal Officer & Secretary | 689.7K | male |
| Marella Thorell | Executive VP, CFO & Treasurer | 667.1K | female |
| Teresa L. Young | Executive Vice President and Chief Commercial & Strategy Officer | 606.3K | — |
| Matthew R. Henn | President & Chief Scientific Officer | 492.4K | — |
| Chris McChalicher | Executive Vice President & Chief Technology Officer | 142.7K | male |
| Richard N. Kender | Interim CEO & Executive Chair | 72.5K | male |
| Ann Kurowski | Senior Vice President of Regulatory Affairs | — | female |
| Kelly Brady | Executive VP & COO | — | female |
| Dennis Walling | Senior Vice President of Clinical Development & Head of Clinical Research | — | — |
| Caroline Hensley | Assistant General Counsel | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MCRB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
